Oxford PharmaGenesis wins King’s Award following rapid export growth
April 21, 2023 | Awards, Medical Communications, Oxford PharmaGenesis, Publications, medcomms, medical affairs
Oxford PharmaGenesis has been honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the country.
Oxford PharmaGenesis has been honoured with a King’s Award for Enterprise, the UK’s most prestigious business award.
The King’s Award, which was announced today, recognizes the HealthScience communications consultancy’s excellence in international trade, reflected in export growth of 46% between 2019 and 2021. Around 75% of the company’s work is now with clients in mainland Europe, North America and Asia Pacific.
It has consistently doubled its turnover and exports every 5 years.
The award also recognizes the company’s commitment to addressing wider social and environmental issues.
Announced just 3 weeks before the King’s coronation, the award completes a remarkable hat-trick for Oxford PharmaGenesis, as it secured the Queen’s Award for Enterprise in 2015 and 2019. The award comes as the company celebrates its 25th anniversary.
Since launching with one employee in 1998, Oxford PharmaGenesis has recorded consistent growth to become the leading independent HealthScience consultancy, providing communications services to the healthcare industry, professional societies and patient groups in the UK and globally.
Over the last decade alone, the company’s overseas sales have risen from £5.2 million to £29.5 million. Over the same period, the number of full-time employees has risen from 83 in 2021 to more than 500 today. Oxford PharmaGenesis currently employs 436 people in the UK and a further 107 people across the United States, Europe and Australia.
The company’s top five markets are USA (37% of total sales), UK (23%), Switzerland (22%), Denmark (3%) and Sweden (3%).
Oxford PharmaGenesis can use the highly respected King’s Award emblem for the next five years.
The King personally approves the list of award recipients – which this year recognizes just 148 companies.
Oxford PharmaGenesis CEO, Dr Chris Winchester said “This prestigious award recognizes the company’s growth in overseas revenue and profitability. Our unique culture brings out the best in our brilliant and talented team, who continue to develop and grow here with us, thanks to the opportunities we offer and our recognition as a ‘Great Place to Work’.
Based on our experience after securing similar recognition from the late Queen, we expect this award to open doors to new relationships. We are proud to already work with nine of the world’s 10 largest pharmaceutical companies. Energized by this new recognition, we are pressing on with helping clients bring new treatments to patients with unmet clinical needs”.
Oxford PharmaGenesis COO, Dr Richard White said “The growth that this award recognizes has enabled us to invest in building a long-term sustainable future for the company, in developing innovative new services and expanding our environmental, social and governance activities (ESG). The King’s Award emblem will stand alongside the silver medal for ESG that we recently received from EcoVadis, the leading global ratings platform. We are committed to working with our loyal clients, partners and suppliers to deliver innovation and sustainability, partnering with charities, academic institutions and patient groups whenever possible”.
Company founder and Chairman, Dr Graham Shelton said “We’re thrilled to receive a King’s Award in the year we are celebrating both the King’s coronation and the company’s 25th anniversary. Since launching Oxford PharmaGenesis in Oxford, UK, I have been proud of the virtuous circle that has seen talented people delivering high-quality services to our clients, resulting in sustained growth. We value our independent status, which helps us build trust between clients and colleagues, all of whom share our passion for providing better treatments to patients throughout the world”.
The King’s Award will be presented to Oxford PharmaGenesis by the King’s representative in Oxfordshire, the Lord-Lieutenant Mrs Marjorie Glasgow, BEM, later this year. Dr Shelton will attend a reception hosted by His Majesty, King Charles III, to be held at Buckingham Palace in June.
Find out more here.
This content was provided by Oxford PharmaGenesis
Company Details
Latest Content from Oxford PharmaGenesis
ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies.
HealthScience communications consultancy wins King’s Award
Oxford PharmaGenesis, the global HealthScience communications consultancy, was honoured on Friday 7 July, by a visit from King Charles III’s representative in Oxfordshire, Lord-Lieutenant Marjorie Glasgow BEM.
The MM+M Agency 100 report: Oxford PharmaGenesis is recognized as an industry leader for the third year running
We have scored a hat-trick, with media brand Medical Marketing and Media (MM+M) listing Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.
Oxford PharmaGenesis wins King’s Award following rapid export growth
Oxford PharmaGenesis has been honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the country.
Pharmaceutical companies reduce own greenhouse gas emissions, but action on supply chains needed
DPhil student, Dr Amy Booth (University of Oxford) and Oxford PharmaGenesis CEO, Dr Chris Winchester, have co-authored a new study published in the International Journal of Environmental Research and Public...
Ten unbeatable reasons to explore a career with Oxford PharmaGenesis in 2022
It’s a new year, and a time when many people reflect on whether their role is providing the opportunities, enjoyment and sense of purpose that they deserve. If this sounds...